TheraRadar
Data updated: May 26, 2026

TRANYLCYPROMINE SULFATE

CNS Approved 2006-06-29

TRANYLCYPROMINE SULFATE is indicated for the treatment of Major Depressive Disorder.

Source: FDA Label • NOVITIUM PHARMA

How TRANYLCYPROMINE SULFATE Works

The antidepressant effect of tranylcypromine sulfate is believed to stem from the potentiation of monoamine neurotransmitter activity within the central nervous system. The drug achieves this by irreversibly inhibiting the enzyme monoamine oxidase. By blocking this enzyme, the medication increases the availability of neurotransmitters, though the full mechanism of action is not completely understood.

Source: FDA Label
3
Indications
--
Phase 3 Trials
19
Years on Market

Details

Status
Prescription
First Approved
2006-06-29
Routes
ORAL
Dosage Forms
TABLET

TRANYLCYPROMINE SULFATE Approval History

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
7 FDA actions from 2006 to 2024
Jun 2024 SUPPL
Label · Labeling
Jun 2022 ORIGINAL
Update
Apr 2018 ORIGINAL
Update

What TRANYLCYPROMINE SULFATE Treats

1 indications

TRANYLCYPROMINE SULFATE is approved for 1 conditions since its original approval in 2006. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Major Depressive Disorder
Source: FDA Label

TRANYLCYPROMINE SULFATE Boxed Warning

SUICIDAL THOUGHTS AND BEHAVIORS and HYPERTENSIVE CRISIS WITH SIGNIFICANT TYRAMINE USE Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors [ see Warnings and Precautions (5.1) ]. Tranylcypromine sulfate is not approved for use in pediatric patients [ see Use in...

TRANYLCYPROMINE SULFATE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to TRANYLCYPROMINE SULFATE

3 of 20

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

APLENZIN
BUPROPION HYDROBROMIDE
1 shared
BAUSCH
Shared indications:
AUVELITY
BUPROPION HYDROCHLORIDE
1 shared
AXSOME
Shared indications:
CAPLYTA
LUMATEPERONE TOSYLATE
1 shared
INTRA-CELLULAR
Shared indications:
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TRANYLCYPROMINE SULFATE FDA Label Details

Indications & Usage

TRANYLCYPROMINE SULFATE is indicated for the treatment of Major Depressive Disorder.

⚠️ BOXED WARNING

WARNING: SUICIDAL THOUGHTS AND BEHAVIORS and HYPERTENSIVE CRISIS WITH SIGNIFICANT TYRAMINE USE Suicidal Thoughts and Behaviors Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated...

Looking for the branded version?

PARNATE

Full clinical data, patents, trials, and competitive landscape for tranylcypromine sulfate.

See PARNATE

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.